An immunocompetent murine model of metastatic mammary cancer accessible to bioluminescence imaging.
Masaaki Shibataa, Eiko Shibata, Junji Morimoto, Nabil A. S. Eid, Yoshihisa Tanaka, Masahito Watanabe, Yoshinori Otsuki
- aDepartment of Anatomy and Cell Biology, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan. shibatam@art.osaka-med.ac.jp
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
BACKGROUND: Many areas of research, including gene and pharmacological therapeutics, would benefit from longitudinal in vivo monitoring methodologies. To investigate the feasibility of one such methodology, we developed a murine mammary cancer model amenable to sequential bioluminescent imaging of tumor growth and metastasis in living animals. MATERIALS AND METHODS: Metastatic mouse mammary carcinoma BJMC3879 cells were transfected to stably express firefly luciferase and inoculated into immunocompetent female BALB/c mice. RESULTS: Sequential analysis using bioluminescent imaging showed increasing photon counts correlated to expanding mammary tumor volumes; in addition, strong signals from axillary, mandibular, femoral, thoracic and abdominal regions in mice were histopathologically determined to be due to metastases, the majority of which occurred in lymph nodes and lungs. CONCLUSION: The bioluminescent mouse mammary cancer model we established provides a method for quantifiable longitudinal in vivo imaging that can be used in gene and pharmacological therapy applications.
TL;DRThe bioluminescent mouse mammary cancer model established provides a method for quantifiable longitudinal in vivo imaging that can be used in gene and pharmacological therapy applications. (Semantic Scholar)